Predictive factors of early pregnancy loss during in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI): retrospective study on 1806 embryo transfers

Karine Morcel
Brest University Hospital

Philippe Merviel (philippe.merviel@chu-brest.fr)
Brest University Hospital

Pandora James
Brest University Hospital

Sarah Bouée
Brest University Hospital

Mathilde Le Guillou
Brest University Hospital

Diane Pertuisel
Brest University Hospital

Jean-Jacques Chabaud
Brest University Hospital

Sylvie Roche
Brest University Hospital

Aurore Perrin
Brest University Hospital

Hortense Drapier
Brest University Hospital

Damien Beauvillard
Brest University Hospital

Article

Keywords: Early pregnancy loss, IVF/ICSI, Ongoing pregnancy, predictive factor

Posted Date: March 16th, 2023

DOI: https://doi.org/10.21203/rs.3.rs-2657747/v1
Abstract

Early pregnancy loss (EPL) is a spontaneous miscarriage of a clinical pregnancy during the first trimester. Several factors of EPL have been studied but results were discordant. We performed a retrospective study in our ART center, comparing baseline data and IVF/ICSI outcomes between cycles with EPL, ongoing pregnancy and without pregnancy. Ectopic pregnancies and biochemical pregnancies (without visualization of a gestational sac on ultrasound) were excluded. The aim of this study is to compare these different cycles, and analyze the risk factors for EPL.

We included 2555 IVF/ICSI cycles leading to 2193 oocyte pick-ups and 1806 embryo transfers. Several characteristics (women's age, infertility diagnosis and duration, estradiol level on the day of hCG-trigger, endometrial thickness, day of embryo transfer) appeared to be risk factors of EPL in univariate analysis. Only women's age has a significant (p < 0.001) influence in multivariate analysis on the rate of EPL, with an OR: 1.71 if the woman's age ≥ 35 years old (reference < 35 y.o = 1), 2.96 if ≥ 38 y.o and 5.31 if ≥ 40 y.o.

In this study, we observed an increase in EPL rate by 4.15% per year in women over 35 years of age.

Introduction

Assisted reproductive technologies (ART) are used to treat infertility and obtain a healthy child. In vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), one of the ARTs, is a procedure with many steps, i/ oocytes obtained after controlled ovarian stimulation, ii/ fertilization by spermatozoa, iii/ intrauterine embryo transfer, thus allowing to study the risk factors of EPL at each stage.

Although the clinical pregnancy rate (CPR) has improved over the last decade, the live birth rate (LBR) remains low, only 38.1% in IVF/ICSI procedure [1]. Pregnancy loss (PL) was the spontaneous miscarriage of an embryo in the first trimester, including non-visualized pregnancy on ultrasound (biochemical pregnancy), ectopic pregnancy, and early clinical pregnancy loss (EPL). Several risk factors for EPL have been identified, such as maternal age, specially after 35 years old (y.o) [2, 3], overweight and obese women [4], in case of polycystic ovary syndrome (PCOS) [5, 6], thin endometrial thickness [7], low ovarian reserve [8, 9], and ovulatory dysfunction [10], but the results of these studies are often subject to debate.

The main objective of this retrospective study was to compare demographic, clinical and biological characteristics in the EPL, ongoing pregnancy and no pregnancy groups after IVF/ICSI and fresh embryo transfer, and to analyze risk factors for EPL. In a second phase, we studied the rates of biochemical pregnancies, ectopic pregnancies, early pregnancy loss according to the women's age ranges (<35, ≥ 35, ≥ 38, and ≥ 40 y.o).

Material And Methods

After an infertility evaluation (for women, serum assays of FSH, LH, estradiol-17β (E2), prolactin and AMH on the second or third day of the menstrual cycle, pelvic ultrasonography, hysterosalpingography followed by laparoscopy and/or hysteroscopy if the results were abnormal; for men a spermogram and a
sperm motility test), all couples were enrolled in IVF/ICSI at the ART center in Brest University Hospital. The antral follicle count (AFC) was not a necessary variable for including and treating patients. All hormonal blood tests and semen examinations were performed in the same laboratory.

**Inclusion and exclusion criteria**

The inclusion criteria were women aged 18–42 y.o and men aged 18–59 y.o, with written consent for infertility treatment. Tubal infertility and endometriosis were established after laparoscopy, uterine infertility (polyp, myoma, malformation, synechiae) after hysteroscopy and treatment of these cases, and the diagnosis of polycystic ovary syndrome (PCOS) was in accordance with the Rotterdam criteria. Masculine infertility is defined as a total mobile count ≤ 1 million spermatozoa. Mixed infertility is the combination of male and female infertility factors. We excluded cycles involving donor gametes or embryos.

**Procedure**

The long GnRH agonist protocol begins on the 20th day of the previous cycle with the daily injection of triptorelin 0.1 mg per day (/d) (Decapeptyl®, Ipsen Pharma, Paris, France), followed 14 days later by an assessment of ovarian desensitization (estradiol level < 50 pg/ml, LH < 3 IU/l and progesterone < 1 ng/ml). When this stage is reached, we decreased the triptorelin to 0.05 mg/d and associate it with a gonadotropin (Fostimon®, Genevrier, Sophia-Antipolis, France; Gonal-F®, Merck, Lyon, France; Puregon®, MSD, Levallois-Perret, France; or Menopur®, Ferring SAS, St Prex, Switzerland) whose dose depends on the women’s age, the basal hormonal balance and the previous ovarian stimulation results.

The short antagonist protocol consists of starting a gondotropin on the 2nd day of the cycle and adding ganirelix (Orgalutran®, MSD, Levallois-Perret, France) when the the follicle size exceeded 14 mm or when the E2 level was over 400 pg/ml. The first evaluation, combined hormone assays (E2, LH, and progesterone) and a vaginal ultrasound examination of the number and size of follicles and the endometrial maturation (thickness and pattern), is carried out on the 5th day of stimulation for the antagonist protocol and on the 7th day for the agonist protocol, with an adaptation of the gonadotropin doses according to the results. This evaluation was repeated every two or three days, depending on the follicular growth. The triggering of ovulation by 250 µg of recombinant human chorionic gonadotropin (Ovitrelle®, Merck, Lyon, France) is decided when at least three follicles ≥ 17 mm diameter and endometrium thickness > 7 mm with a triple-line pattern were observed, and oocyte pick-up is performed 35–37 hours after. The support of the luteal phase is started on the evening of the follicular puncture, with 400 mg/d of intravaginal micronized progesterone (Utrogestan®; Besins International, Paris, France), until the β-hCG dosage 15 days after.

After observing fertilization 18h after incubation, the embryos are then maintained in vitro culture 2 to 3 days (D2 or D3 cleaved embryos) or 5 to 6 days (D5 or D6 blastocysts), according to their evolution. The classification of cleaved embryos is that of the French IVF biologists association (BLEFCO), and the blastocysts were evaluated according to Gardner’s classification (supplementary file). One to two
embryos (exceptionally three) were transferred with a Frydman catheter (CCD Laboratories, Paris, France), and the other good embryos were vitrified. The oocyte or embryo “freeze-all” events were decided in cases with (i) an elevated (> 1.5 ng/ml) plasma progesterone level on the hCG trigger day, (ii) ovarian hyperstimulation (> 3500 pg/ml), (iii) a lack of spermatozoa on the day of oocyte retrieval.

The no pregnancy group (No P) consisted of women with a negative β-hCG assay (< 5 IU/l) 2 weeks after embryo transfer. Clinical pregnancy (CP) was confirmed by a gestational sac on ultrasound 3 weeks after embryo transfer and a β-hCG level above 1000 IU/l. Ongoing pregnancy (OP) was defined as a pregnancy > 12 weeks of gestation. Early pregnancy loss (EPL) was a miscarriage of a clinical pregnancy before 12 weeks of gestation.

Ectopic pregnancy and women with a biochemical pregnancy (β-hCG assay between 100 and 1000 IU/l without gestational sac on ultrasound) were excluded from the main analysis.

**Statistical analysis**

Statistical comparisons were conducted using either the Student t test or a Mann-Whitney U test for continuous variables and a Chi 2 test or Fisher exact test for qualitative variables. The multivariate analysis included all data for which there was a significant difference between EPL and OP groups (woman's age, duration of infertility, infertility diagnosis, E2 level on the day of hCG trigger, endometrial thickness, number of embryos transferred, day of embryo transfer). The rate of EPL in women < 35 y.o was used as a reference. We used the XLSTAT® add-in (Addinsoft, Paris, France) program for statistical analysis. The statistical significance was set at p < 0.05.

**Ethical approval and consent to participate**

All the subjects have signed consent to the infertility treatment (ART French legislation). For this study, an informed consent was obtained from all subjects and/or their legal guardians. The consents of each subject are available in their medical record and with the corresponding author. This study was approved by the Brest Institutional Review Board (2020, June 18) as an ancillary study under the authorization reference B2020CE.43.

**Results**

We studied 2555 IVF/ICSI cycles (c) at the ART center of Brest university hospital between 2015 and 2020. These cycles resulted in 2193 oocyte pick-ups (OPU) (85.8% of the cycles) and 1806 embryo transfers (t) (82.3% of the OPU). We have observed 362 cancelations during ovarian stimulation (14.1% of the cycles), 24 oocyte pick-ups without oocytes (1.1%), 75 freeze all procedures (3.4%) and 288 embryo culture failures (13.1%). After removing biochemical pregnancies (n: 74; 10.9%) and ectopic pregnancies (n: 26; 3.8%), we obtained 574 clinical pregnancies (31.7%/t), of which 140 early pregnancy losses (24.4%) and 434 ongoing pregnancies (24.0%/t). Figure 1 summarizes the flow chart of this study.
Table 1 reports the baseline characteristics of couples with EPL, OP and without pregnancy. The clinical pregnancy rate was significantly higher in couples in which were found higher male age, higher female BMI, lower male BMI, lower FSH and AMH levels at day 2 or 3 of the menstrual cycle, and those who had a previous pregnancy after ART. There was no difference between the three groups concerning the history of EPL in previous spontaneous pregnancies or pregnancies obtained after ART. Couples with EPL showed significantly higher female age (p < 0.001), longer duration of infertility (p < 0.01), more frequent mixed cause of infertility (p < 0.001), and less PCOS (p < 0.01) compared with couples with an ongoing pregnancy.

Table 2 shows the clinical and biological results of IVF/ICSI cycles. Clinical pregnancy rate was significantly higher in couples with lower cycle rank, agonist protocol, total gonadotropin dose, stimulation duration, and higher E2 level on hCG day, oocyte retrieved, embryo obtained, number of embryos transferred and embryos frozen. Couples with EPL had significantly higher E2 levels on the day of hCG (p < 0.05), less endometrial thickness (p < 0.05), more embryos transferred (p < 0.001) and a cleavage stage at D2 (p < 0.001) and at D3 (p < 0.05) compared to couples with an ongoing pregnancy.

Table 3 present the data of the type of pregnancy according to the different woman age ranges. In multivariate analysis (Fig. 2), only the woman's age significantly influenced the rate of EPL with an odd-ratio (OR) of 1.71 (95%CI: 1.31–2.11; p < 0.01) (≥ 35 versus < 35 years of age), 2.96 (95%CI: 2.14–3.78; p < 0.001) (≥ 38 versus < 35 years of age), and 5.31 (95%CI: 4.46–6.16; p < 0.001) (≥ 40 versus < 35 years). Thus, we calculated that each additional year beyond the woman's age of 35 years led an increase in EPL by 4.15% per year.

Discussion

In this study, we report a pregnancy loss rate of 35.3% (10.9% biochemical pregnancies and 24.4% of EPL), similar to the rates reported in the United States between 1999–2002 [11] (29%) and by Goldstein where the rate of spontaneous first trimester miscarriage (like EPL) was 15–30% in the general population [12]. In contrast, Yang [7] showed a very low pregnancy loss rate of 19.7% (5.5% biochemical pregnancies and 8.9% of EPL). Two possible explanations for this reduction of pregnancy loss were a different luteal phase support by vaginal progesterone gel 90 mg/d (Crinone®, Merck, Lyon, France) and the transfer of more embryos (3 embryos in 23.6% of cases). After identification of embryonic heart activity, the rate of late pregnancy loss remains around 3–4% [13].

Clinical studies have confirmed that EPL increased with the maternal age, especially after 35 y.o [2, 3]. Yang [7], in 15210 pregnancies following an embryo transfer (LBR 77.6%), showed a multivariate OR in women aged ≥ 35 years of 1.49 (CI95%: 1.22–1.83) and ≥ 40 years of 3.82 (CI95%: 2.65–5.51) compared with women < 35 years. This author showed that the risk of EPL increases by 22% per year in a woman older than 36 years of age. These values were similar to the results of our study (≥ 35 yo: 1.71 and ≥ 40: 5.31). The main causes of EPL with the maternal age appear to be chromosomal aneuploidy [14, 15] and decreased ovarian reserve [16]. Preimplantation genetic diagnosis (PGD) before embryo
transfer may reduce the EPL in relation with aneuploidy. After PGD, Verlinsky [17] reports a 4-fold reduction in the rate of EPL when the couple has a Mendelian anomaly, and Grifo [18] shows a 35–6% reduction of EPL. However, the safety and the risks of this technology need to be further investigated.

Regarding paternal age, Marsidi [19] showed that the increase in EPL rate observed above 45 y.o disappeared when women were younger than 35 y.o, in relation with the best oocyte quality. In the Yi’s study [20], the mean maternal age (32.6 +/- 4.3 vs. 30.5 +/- 4.2, p < 0.001) and the infertility duration (5 [3-8.5] vs. 4 [3–7]; p: 0.03) were significantly higher in the EPL group than in the OP group. This result may be attributed to oocyte deterioration and endocrine variations that occur with advanced maternal age [21]. Yang [7] showed that PCOS was an independent risk factor for late pregnancy loss, but not for EPL (OR: 1.14; CI95%: 0.94–1.37). The relationship between PCOS and EPL could be secondary to high secretions of LH and testosterone in these patients [22]. However, GnRH agonist therapy has not shown a beneficial effect on pregnancy outcomes [23]. In contrast, Rai in 2000 [24] showed that neither a LH level > 10 IU/l nor a testosterone level > 3 nmoles/l were associated with an increase of EPL. Obesity, which is common in this condition, could be an independent and confounding risk factor of miscarriage.

Munch [25] showed that high doses of gonadotropins decreased the probability of pregnancy after fresh embryo transfers but not after frozen embryo transfers, suggesting an impact on the endometrium and not on embryo quality. Supraphysiological levels of estradiol may affect implantation and migration of trophoblasts [26], as shown by the difference in endometrial gene expression in this case [27, 28]. Thus, the proportion of euploid oocytes is directly and positively related to the number of mature oocytes and inversely related to the total FSH dose per oocyte and per mature oocyte [29, 30, 31]. Similarly, in the Kaleli’s study, the FSH dose is related to the aneuploidy in the granulosa cells [32]. Serum estradiol level reflects follicular maturation and oocyte quality, and has a significant influence on endometrial maturation [33]. According to Taheri [34], the serum E2 level on the hCG day appeared to be a negative predictive factor for live births (OR [95%CI]: 0.99 [0.99-1]). According to Blazar’s study [35], the serum E2 cut-off for pregnancy is 2500 pg/ml. In the study by Li [36], the optimal serum E2 level on the trigger day for obtaining a pregnancy after a fresh embryo transfer is between 1000 and 3148 pg/ml (AUC-ROC: 0.721).

Studies have concluded that endometrial thickness (with a threshold of 10 mm) is strongly associated with pregnancy outcomes after IVF/ICSI treatment [37]. For Yang [7], a negative correlation was observed between endometrial thickness and EPL (OR 0.95; CI95% 0.92–0.97), and del Carmen Nogales [38] observed a significant association between endometrial thickness and EPL (OR: 0.65; 95% CI: 0.52–0.77, p: 0.04). For Liu [39], the pregnancy loss rate increased with each millimeter decline in fresh cycles, but Yang [7] showed that there was no significant difference when the endometrial thickness was greater than 8 mm (as in the Vuong’s study [40]). Zhao [41] reported embryo implantation rates over 30% when endometrial thickness was between 8 and 16 mm (AUC: 0.596; CI95%: 0.571–0.621), and the meta-analysis by Kasius [42] showed that the pregnancy rate increased with endometrial thickness (starting at 7 mm, in a univariate analysis). However, Sundström [43] reported a pregnancy with an endometrial thickness of 4 mm and Check [44] with an endometrial thickness of 3.6 mm. Remohi [45] showed that 60% of women with an endometrial thickness between 6.0 and 6.9 mm had successful pregnancies.
In our study, embryo quality is not a risk factor for EPL, as in the del Carmen Nogales's study [38] which reported an EPL rate of 13.1% with no difference between embryo quality classes A (11.3%), B (12.8%), C (11.8%) and D (12.5%). Non blastocyst transfers have a higher risk of abnormal implantation than blastocyst transfers (OR: 1.19; CI95% 1.17–1.21) [45]. Our ART center policy is to transfer embryos at the blastocyst stage (day 5 or 6) whenever possible. Wang [46] showed that fresh blastocyst transfers had a lowest risk of biochemical pregnancy and pregnancy loss than cleaved embryo transfers in women < 40 y.o. However this study did not account for cleavage stage vs. blastocyst, which has a significant interaction with the outcomes and may explain the differences. Women who transferred ≥ 2 embryos showed lower risk of EPL than women who transferred a single embryo: multivariate OR for 2 embryo transferred : 0.63 (CI 95% 0.49–0.82) and for 3 : 0.47 (CI95% 0.34–0.66) [7]. A meta-analysis of three trials of 633 cycles in women 27–33 years old demonstrated higher clinical and ongoing pregnancy rates in frozen/thawed embryo transfers compared with fresh embryo transfers [47]. For Yang [7], there was an increased risk of EPL after frozen-thawed ET versus fresh ET (OR 1.12; CI 1.01–1.24). Hipp [48] reported an increased risk of first-trimester pregnancy loss after the transfer of frozen embryos compared with fresh embryos in women < 38 y.o, and this difference persisted in women < 30 y.o.

This study did not show an impact of BMI on the EPL risk (26.8% of women were overweight and 16% were obese in all cycles), as in our previous study where we did not find an association between clinical pregnancy and live birth rates and different BMI classes [49]. Similarly, Brunet [50] reported that after adjustment, obesity, including classes II/III, had no impact on EPL rates. Provost [4] showed that pregnancy outcomes were most favorable in low or normal weight cohorts but progressively worsened with increasing BMI in fresh cycles. For Yang [7], the multivariate OR in case of BMI ≥ 30 was 1.47 (CI95% 1.14–1.91) but no significant among BMI 25–30. Others studies have shown that obesity is a risk factor for EPL after IVF/ICSI [51, 52]. Impaired stromal decidualization in obese women has been observed [53], in relation to insulin and leptin resistance, and decreased glycodelin, IGF BP1 (insulin-like growth factor binding protein 1) and PAI 1 (plasminogen activator inhibitor 1).

In this study, uterine infertility was defined by a history of polyp, myoma, malformation or synechiae, treated by operative hysteroscopy with subsequent uterine cavity control. Yang [7] showed a multivariate OR of 1.77 (CI95% 1.32–2.38) when there was endo-uterine pathology. However, for congenital uterine malformations other than a septal uterus, the surgery fails to increase the live birth rate or decrease EPL [54].

In this study, clinical pregnancy rates were significantly higher in couples who had a prior pregnancy after ART. Magnusson et al [55] evaluated the probability of a live birth in a Swedish series of 77956 fresh transfers between 2007 and 2013. The ideal number of oocytes retrieved was between 10 and 20 (adjusted OR: 1.064), but this variable was less predictive than having previously had a child through IVF (OR: 1.462), but was more predictive than the woman's age (OR: 0.936).

Other factors may also play a role in embryo development, such as vitamin B, which is involved in the synthesis and methylation of nucleic acids and proteins [56]. Methyl tetrahydrofolate reductase (MTHFR)
is one of the key steps in folate metabolism, and the c.677 C>T mutation in the MTHFR gene can alter folate concentration and lead to the development of EPL, as shown in a previous study [57].

One of the strengths of our study is its large sample size - more than 1800 IVF/ICSI embryo transfers in a single assisted reproduction center. Secondly, there is limited literature on risk factors for EPL after IVF/ICSI, and in this study we performed a multivariate analysis of a number of risk factors for EPL according to women's age. However, our study also had several limitations. First, our study was retrospective, had significant demographic differences, and did not take into account cumulative pregnancy rates. Secondly, we did not take into account some confounding factors that had a significant effect on the probability of pregnancy (e.g., poor responders or low-quality embryo transfers); the only predictor of EPL was the woman's age, which prompted us to analyze our data by age class.

**Conclusion**

In this study, we found in univariate analysis the common risk factors for EPL (woman's age, duration of infertility, diagnosis of infertility, estradiol level on the day of hCG trigger, endometrial thickness, number of embryos transferred, and day of embryo transfer), but in multivariate analysis, only the woman's age was retained as a significant risk factor. Thus, we calculated that each additional year beyond the age of 35 years led to an increase in EPL rate by 4.15% per year. Further prospective studies are needed to confirm these results.

**Abbreviations**

ART: assisted reproductive technology

AUC-ROC: area under the curve - receiver operating curve

BMI: body mass index

c: cycle

CI 95%: confidence interval at 95%

CPR: clinical pregnancy rate

dhCG: day of hCG

/d: per day

E2: estradiol-17β

EPL: early pregnancy loss

IU: international unit
IVF/ICSI: in vitro fertilization/intracytoplasmic sperm injection

LBR: live birth rate

MII: mature oocyte in metaphase II

N: number

No P: no pregnancy

NS: not significant

OP: ongoing pregnancy

OPU: oocyte pick-up

OR: odd ratio

PCOS: polycystic ovary syndrome

PGD: preimplantation genetic diagnosis

PL: pregnancy loss

t: transfer

WA: woman age

y: year

y.o: years old

Declarations

Acknowledgements

The authors thanks Pandora James for her comments, suggestions and critical reading of the manuscript.

Consent to publish

The manuscript has been read and approved by all authors. The authors confirm that all methods were carried out in accordance with relevant guidelines and regulations.

Availability of data and materials
The material contained in this manuscript has not been published, has not been submitted or is not being submitted elsewhere. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors report no conflicts of interest in relation to the present study.

**Funding**

Not applicable

Authors' contributions

- Karine Morcel, Philippe Merviel: substantial contributions to the conception, design of the work, the acquisition, analysis and interpretation of data; have drafted the work or substantively revised it
- Pandora James: comments, suggestions and critical reading of the manuscript
- Sarah Bouée, Mathilde Le Guillou, Diane Pertuisel, Jean-Jacques Chabaud, Sylvie Roche: the acquisition of clinical data
- Aurore Perrin, Hortense Drapier, Damien Beuvillard: the acquisition of biological data

Each author has approved the submitted version and has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

**References**


**tables**

**Table 1**: Baseline data of the different groups: early pregnancy loss, ongoing pregnancy and no pregnancy
<table>
<thead>
<tr>
<th></th>
<th>EPL (A)</th>
<th>OP (B)</th>
<th>No P (C)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number</strong></td>
<td>140</td>
<td>434</td>
<td>1132</td>
<td></td>
</tr>
<tr>
<td><strong>Woman age y.o</strong></td>
<td>31.6 ± 5.7</td>
<td>29.8 ± 4.2</td>
<td>29.9 ± 4.6</td>
<td>A-B*** ; A-C***</td>
</tr>
<tr>
<td><strong>Man age y.o</strong></td>
<td>36.5 ± 7.3</td>
<td>36.9 ± 10.5</td>
<td>35.1 ± 7.0</td>
<td>A-C* ; B-C***</td>
</tr>
<tr>
<td><strong>Woman BMI kg/m²</strong></td>
<td>25.7 ± 4.8</td>
<td>24.8 ± 5.0</td>
<td>24.0 ± 4.5</td>
<td>A-C*** ; B-C**</td>
</tr>
<tr>
<td><strong>Man BMI kg/m²</strong></td>
<td>25.2 ± 4.8</td>
<td>25.6 ± 3.6</td>
<td>26.5 ± 4.9</td>
<td>A-C** ; B-C***</td>
</tr>
<tr>
<td><strong>Woman tobacco use %</strong></td>
<td>27.8</td>
<td>27.6</td>
<td>23.1</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Man tobacco use %</strong></td>
<td>35.0</td>
<td>34.8</td>
<td>28.7</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Infertility diagnosis %</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCOS</td>
<td>14.2</td>
<td>14.2</td>
<td>17.0</td>
<td>NS</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>11.4</td>
<td>17.0</td>
<td>12.0</td>
<td>A-B** ; B-C**</td>
</tr>
<tr>
<td>Uterine</td>
<td>8.5</td>
<td>4.6</td>
<td>2.9</td>
<td>A-C***</td>
</tr>
<tr>
<td>Male factor</td>
<td>6.4</td>
<td>3.2</td>
<td>4.5</td>
<td>NS</td>
</tr>
<tr>
<td>Mixed</td>
<td>59.2</td>
<td>61.0</td>
<td>57.5</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>21.2</td>
<td>9.9</td>
<td>6.1</td>
<td>A-B*** ; A-C*** ; B-C**</td>
</tr>
<tr>
<td>Basal FSH (IU/l)</td>
<td>6.5 ± 1.7</td>
<td>6.7 ± 2.3</td>
<td>7.4 ± 1.9</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Basal AMH (ng/ml)</td>
<td>1.9 ± 1.3</td>
<td>2.0 ± 1.2</td>
<td>1.6 ± 1.1</td>
<td>A-C** ; B-C***</td>
</tr>
<tr>
<td><strong>Pregnancies without ART %/couple</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy losses %/pregnancy</td>
<td>24.2</td>
<td>23.7</td>
<td>21.2</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>15.2</td>
<td>18.1</td>
<td>15.8</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Pregnancies with previous ART %/couple</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy losses %/pregnancy</td>
<td>14.2</td>
<td>17.2</td>
<td>7.0</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td></td>
<td>20.0</td>
<td>18.6</td>
<td>15.0</td>
<td>NS</td>
</tr>
</tbody>
</table>
Infertility duration y

|        | 4.2 ± 2.5 | 3.6 ± 1.8 | 4.0 ± 2.3 | A-B**; B-C*** |

Legends: EPL: early clinical pregnancy loss; OP: ongoing pregnancy; No P: no pregnancy; y.o: years old; BMI: body mass index; PCOS: polycystic ovarian syndrome; ART: assisted reproductive technology; y: years

Statistical analysis p: *: < 0.05; **: < 0.01; ***: < 0.001; NS: not significant

**Table 2**: IVF/ICSI procedures and outcomes in the different groups: early pregnancy loss, ongoing pregnancy and no pregnancy
<table>
<thead>
<tr>
<th></th>
<th>EPL (A)</th>
<th>OP (B)</th>
<th>No P (C)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>140</td>
<td>434</td>
<td>1132</td>
<td></td>
</tr>
<tr>
<td>Cycle rank</td>
<td>$1.6 \pm 0.7$</td>
<td>$1.7 \pm 1.1$</td>
<td>$1.9 \pm 1.2$</td>
<td>A-C*** ; B-C**</td>
</tr>
<tr>
<td>Agonist protocol %</td>
<td>59.2</td>
<td>65.6</td>
<td>79.5</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Total FSH dose IU</td>
<td>$2326 \pm 1360$</td>
<td>$2129 \pm 979$</td>
<td>$2676 \pm 1374$</td>
<td>A-C** ; B-C***</td>
</tr>
<tr>
<td>Stimulation duration day</td>
<td>$10.9 \pm 1.9$</td>
<td>$11.2 \pm 2.1$</td>
<td>$11.6 \pm 2.4$</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Estradiol at dhCG pg/ml</td>
<td>$2639 \pm 896$</td>
<td>$2401 \pm 1108$</td>
<td>$2189 \pm 853$</td>
<td>A-B* ; A-C*** ; B-C***</td>
</tr>
<tr>
<td>Endom thickness mm</td>
<td>$10.7 \pm 2.0$</td>
<td>$11.1 \pm 2.4$</td>
<td>$10.7 \pm 2.1$</td>
<td>A-B* ; B-C**</td>
</tr>
<tr>
<td>Total oocytes</td>
<td>$13.3 \pm 4.9$</td>
<td>$14.1 \pm 5.9$</td>
<td>$9.4 \pm 4.9$</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>MII oocytes</td>
<td>$10.0 \pm 3.6$</td>
<td>$9.9 \pm 4.7$</td>
<td>$6.6 \pm 4.0$</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Fertilized oocytes</td>
<td>$6.1 \pm 2.8$</td>
<td>$6.1 \pm 3.1$</td>
<td>$3.0 \pm 2.3$</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Total embryos</td>
<td>$6.5 \pm 2.8$</td>
<td>$6.5 \pm 2.8$</td>
<td>$3.0 \pm 2.6$</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Fertilization + clivage rate %</td>
<td>65.5</td>
<td>65.6</td>
<td>45.8</td>
<td>A-C*** ; B-C***</td>
</tr>
<tr>
<td>Embryo grades A %</td>
<td>40.0</td>
<td>47.0</td>
<td>37.7</td>
<td>NS</td>
</tr>
<tr>
<td>B %</td>
<td>18.0</td>
<td>20.0</td>
<td>21.5</td>
<td>NS</td>
</tr>
<tr>
<td>C %</td>
<td>30.0</td>
<td>26.0</td>
<td>30.4</td>
<td>NS</td>
</tr>
<tr>
<td>D %</td>
<td>12.0</td>
<td>7.0</td>
<td>10.4</td>
<td>NS</td>
</tr>
<tr>
<td>Embryo transferred</td>
<td>$2.0 \pm 0.4$</td>
<td>$1.7 \pm 0.4$</td>
<td>$1.2 \pm 0.4$</td>
<td>A-B*** ; A-C*** ; B-C***</td>
</tr>
<tr>
<td>Twin pregnancy %</td>
<td>10.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day embryo transfer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 2 %</td>
<td>70.0</td>
<td>52.0</td>
<td>70.7</td>
<td>A-B*** ; B-C**</td>
</tr>
<tr>
<td>Day 3 %</td>
<td>22.0</td>
<td>33.0</td>
<td>18.9</td>
<td>A-B* ; B-C***</td>
</tr>
<tr>
<td>Day 5 or 6 %</td>
<td>8.0</td>
<td>15.0</td>
<td>10.4</td>
<td>A-B* ; B-C*</td>
</tr>
<tr>
<td>Couple with cryopreserved embryo %/transfer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>m ± SD</td>
<td>$36.4 \pm 3.6$</td>
<td>$48.3 \pm 0.5$</td>
<td>$20.6 \pm 0.5$</td>
<td>A-B* ; A-C*** ; B-C***</td>
</tr>
<tr>
<td></td>
<td>$3.6 \pm 0.5$</td>
<td>$3.7 \pm 0.4$</td>
<td>$3.4 \pm 0.6$</td>
<td>A-B* ; A-C*** ; B-C***</td>
</tr>
</tbody>
</table>
Legends: EPL: early clinical pregnancy loss; OP: ongoing pregnancy; No P: no pregnancy; IU: international unit; dhCG: day of hCG administration; MII: mature oocyte (metaphase II)

Statistical analysis p: *: < 0.05; **: < 0.01; ***: < 0.001; NS: not significant

Table 3: Data of total pregnancies, biochemical and extra-uterine pregnancies, ongoing pregnancies and early clinical pregnancy losses in age classes

<table>
<thead>
<tr>
<th></th>
<th>WA &lt; 35 years old</th>
<th>WA ≥ 35 years old</th>
<th>WA ≥ 38 years old</th>
<th>WA ≥ 40 years old</th>
</tr>
</thead>
<tbody>
<tr>
<td>N cycles (c)</td>
<td>1171</td>
<td>1384</td>
<td>963</td>
<td>653</td>
</tr>
<tr>
<td>N transfers (t)</td>
<td>899 (76.7%/c)</td>
<td>907 (65.5%/c)</td>
<td>539 (55.9%/c)</td>
<td>320 (49.0%/c)</td>
</tr>
<tr>
<td>Without pregnancy (No P)</td>
<td>530</td>
<td>602</td>
<td>383</td>
<td>226</td>
</tr>
<tr>
<td>Total pregnancies (β-hCG &gt; 100 IU/l)</td>
<td>369 (41.0%/t)</td>
<td>305 (33.6%/t)**</td>
<td>156 (28.9%/t)***</td>
<td>94 (29.3%/t)***</td>
</tr>
<tr>
<td>Biochemical pregnancies (% of total pregnancies)</td>
<td>31 (8.4)</td>
<td>43 (14.0)*</td>
<td>35 (22.4)***</td>
<td>29 (30.8)***</td>
</tr>
<tr>
<td>Ectopic pregnancies (% of total pregnancies)</td>
<td>15 (4.0)</td>
<td>11 (3.6) NS</td>
<td>7 (4.4) NS</td>
<td>3 (3.2) NS</td>
</tr>
<tr>
<td>Clinical pregnancies (CP)</td>
<td>323 (35.9%/t)</td>
<td>251 (27.7%/t)***</td>
<td>114 (21.1%/t)***</td>
<td>62 (19.4%/t)***</td>
</tr>
<tr>
<td>Early pregnancy losses (EPL) (% of clinical pregnancies)</td>
<td>57 (17.6)</td>
<td>83 (33.0)***</td>
<td>51 (44.7)***</td>
<td>34 (54.8)***</td>
</tr>
<tr>
<td>Ongoing pregnancies (OP)</td>
<td>266 (29.5%/t)</td>
<td>168 (18.5%/t)***</td>
<td>63 (11.6%/t)***</td>
<td>28 (8.7%/t)***</td>
</tr>
</tbody>
</table>

Legends: WA: woman age; N: number; c: cycle; t: transfer

Statistical analysis between women < 35 and ≥ 35 y.o, < 35 and ≥ 38 y.o, < 35 and ≥ 40 y.o: *: p < 0.05; **: p < 0.01; ***: p < 0.001; NS: not significant

Figures
**Figure 1**
Flow chart of the study

**Figure 2**
Relative risks of EPL in the different woman age groups in a multivariate analysis. The EPL rate in women < 35 yo served as the reference (= 1). The multivariate analysis included the woman age, infertility...
duration, type of infertility, estradiol level on hCG day, endometrial thickness, number of embryo transferred and day of embryo transfer.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaryfile.docx